CRISPR Therapeutics AG (CRSP) Asset Utilization Ratio (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Asset Utilization Ratio of 0.0 for Q1 2026, up 5.64% sequentially from 0.0 in Q4 2025, and down 90.38% YoY from 0.02 in Q1 2025.
CRISPR Therapeutics AG (CRSP) Asset Utilization Ratio (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Asset Utilization Ratio for 11 years, with the latest figure at 0.0 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 90.38% year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (down 90.38% YoY) and the FY2025 annual result came in at 0.0, down 90.67% from the prior year.
- Asset Utilization Ratio rose to 0.0 in Q1 2026 per CRSP's latest filing, from 0.0 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.34 in Q1 2022 and troughed at 0.0 in Q4 2022.
- A 5-year average of 0.06 and a median of 0.02 in 2025 frame the typical range for Asset Utilization Ratio.
- The widest YoY moves for Asset Utilization Ratio: up 58644.33% in 2022, down 99.84% in 2022.
- Over 5 years, Asset Utilization Ratio stood at 0.0 in 2022, then soared by 32895.55% to 0.17 in 2023, then sank by 90.35% to 0.02 in 2024, then slumped by 90.62% to 0.0 in 2025, then grew by 5.64% to 0.0 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.02 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00 |
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.09 |
| Jun 30, 2024 | 0.08 |
| Mar 31, 2024 | 0.12 |
| Dec 31, 2023 | 0.17 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.08 |
| Mar 31, 2023 | 0.04 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.01 |
| Jun 30, 2022 | 0.01 |
| Mar 31, 2022 | 0.34 |
| Dec 31, 2021 | 0.33 |
| Sep 30, 2021 | 0.32 |